In October 2025, Aerska, an Irish biotechnology company, emerged from its stealth phase with a seed funding round of $21 million, and has since raised an additional $39 million in a Series A funding round. With this new funding, the total amount raised by the company since its inception has reached $60 million. Aerska specializes in developing RNA medicines aimed specifically at treating central nervous system diseases. The company employs innovative brain shuttle technology to enhance the delivery of RNA interference (RNAi) therapeutics across the blood-brain barrier, which is crucial for effectively addressing neurological disorders. The Series A funding round was led by the EQT Dementia Fund and Age1, with significant contributions from Iaso Ventures and existing investors. The raised funds are earmarked to further advance Aerska's brain shuttle technology, enabling the systemic administration of RNAi therapies geared towards treating conditions such as genetically-driven forms of Alzheimer's disease. CEO Jack O'Meara emphasized that this novel approach could unlock transformative treatment options for neurodegenerative diseases by silencing harmful genes and potentially preserving cognitive function and quality of life for patients facing such debilitating conditions. Highlighting the importance of this funding round, O'Meara noted the partnership with the EQT Dementia Fund would critically support Aerska's transition towards clinical applications of its technology, ultimately aiming to create meaningful therapies that can genuinely improve outcomes for patients. The investment also reflects a growing interest in innovative therapies targeting neurological conditions that have long been underserved by traditional treatments. Aerska's emergence as a key player in this space illustrates the potential for biotechnology advancements in creating effective treatment solutions, especially in light of rising incidences of neurodegenerative diseases. With its headquarters located in Dublin, Ireland, Aerska is focused on amplifying its research capabilities, which are also set to expand with operations in London, UK. The CEO, along with co-founders David Hardwicke and Stu Milstein, are rallying their expertise to ensure tangible outcomes from the funding and to bring their promising technologies significantly closer to patients who could benefit from them. The neuroscience domain is increasingly recognizing the potential of RNA-based therapies as critical avenues for intervention to help improve neurological health.